基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌术前化疗期间 TIL（肿瘤浸润淋巴细胞）评估最佳时机的验证
英文原题：Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer.
查看英文原题
Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
乳腺癌 NAC 期间的 TIL 评估，只有在 NAC 开始前 35 天进行时才是预后预测因素。
中文摘要
患者与方法
239例患者接受新辅助化疗（NAC）。通过受试者工作特征（ROC）曲线分析，研究从乳腺癌诊断针吸活检至NAC开始期间的最佳评估时点。
结果
仅在短间隔组（≤35天）观察到TIL与病理完全缓解（pCR）显著相关（p=0.033）。预后分析显示，在短间隔组中，TIL水平高的患者生存预后显著优于TIL水平低的患者（间隔>35天组）；无病生存期（DFS）p=0.001，总生存期（OS）p=0.021。多变量分析确定TIL是影响DFS的独立因素（p=0.008，风险比=0.130）。
结论
乳腺癌NAC期间进行TIL评估，只有在NAC开始前35天内进行时才可作为预后预测指标。
展开英文摘要原文
PATIENTS AND METHODS
Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis.
RESULTS
A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group ( 35 days) (p=0.033). Prognostic analysis revealed that in the short-term group, patients with high TIL levels had a significantly better survival prognosis relative to those with low TIL levels (>35 days) [disease-free survival (DFS): p=0.001, overall survival (OS): p=0.021]. TILs were identified as an independent factor affecting DFS in a multivariate analysis (p=0.008, hazard ratio=0.130).
CONCLUSION
TIL assessment during NAC for breast cancer is a prognostic predictor only when performed at 35 days before NAC initiation.
论文信息
- 作者
- Kashiwagi S、Asano Y、Takada K、Goto W、Kouhashi R、Yabumoto A、Tauchi Y、Morisaki T
- 单位
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.Japan
- 期刊
- Cancer diagnosis & prognosis2022 Jul-Aug
- 原文标识
- PubMed 35813011 · DOI 10.21873/cdp.10127
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →